Although our previous study demonstrated that EMPA, a highly selective SGLT2 inhibitor, may have direct effects in the heart to improve glucose and fatty acid oxidation and increase ATP production in HF (7), the mechanisms involved remain unclear. The gene discussed is SLC5A2; the disease is hydrops fetalis.